**Présentations orales**

- Management of Desmoid Tumours (DT): A nationwide survey after labeling of 2 expert networks (RRePS and NetSarc) - Speaker: N. Penel

- Time interval (TI) between surgery and start of adjuvant radiotherapy (RT): A retrospective analysis of 1150 cases from the French Sarcoma Group - Speaker: J. Fourquet

- Reporting adverse events (AEs) in cancer surgery randomized trial: A systemic analysis of published trials in oesogastric (OG) and gynecological (GY) cancer patients - Speaker: M Meghelli

**Communications affichées**


- Survival benefit, safety, and prognostic factors for outcome with Regorafenib (REG) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study - C de la Fouchardière, B Paule, P Burtin, J Wallet, D Tougeron, LM Dourthe, PL Etienne, L Mineur, C Becuwe, P Maes, J Dauba, P Michel, JL Wendling, B Linot, A Hollebecque, S Lisiant, JF Morere, T André, JM Phelip, A Adenis

- Dose-seeking phase I trials (DSPT) of approved molecularly targeted therapies (MTT): Exhaustiveness and readability of published clinical reports - S. Cousin, A. et al

- Growth modulation index (GMI) to assess salvage chemotherapy benefit after FOLFIRINOX progression in metastatic pancreatic adenocarcinoma - A. Ducoulombier, et al

- Blood vessel endothelial activation, egfl7 expression, and inflammatory infiltrate in breast cancer, D. Pannier, et al

- Prognostic score (REGOSCORE) for survival after Regorafenib (RE) treatment for patients (pts) with pretreated metastatic colorectal cancer (mCRC) - A. Kramar, et al

- Intraperitoneal (IP) chemotherapy (CT) in epithelial ovarian cancer (EOC): A matched case-control study - N. Kotecki, et al.


- Is PROSIGNA useful to determine adjuvant treatment in intermediate prognosis early breast cancer (EBC)? - J. Bonneterre, A. Prat, P. Galvan, S. Giard

- Special Session: Stereotactic Hypofractionated Radiation Therapy for Oligometastatic Disease: For Whom and When?

Chair: E. Lartigau